CN Patent

CN115335060B — 使用突变idh抑制剂的组合疗法

Assigned to Eli Lilly and Co · Expires 2024-11-12 · 2y expired

What this patent protects

本发明涉及使用(a)具有式I的突变体IDH抑制剂和(b)抗代谢剂、低甲基化剂和突变体Flt3(Flt3)抑制剂中的一种或多种的组合疗法，用于治疗癌症。

USPTO Abstract

本发明涉及使用(a)具有式I的突变体IDH抑制剂和(b)抗代谢剂、低甲基化剂和突变体Flt3(Flt3)抑制剂中的一种或多种的组合疗法，用于治疗癌症。

Drugs covered by this patent

Patent Metadata

Patent number
CN115335060B
Jurisdiction
CN
Classification
—
Expires
2024-11-12
Drug substance claim
No
Drug product claim
No
Assignee
Eli Lilly and Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.